Insurance Coverage for Obesity Treatment

Medicare Coverage

Bariatric Surgery (Part A/B)

Medicare covers bariatric surgery for beneficiaries who meet all of the following criteria:

• BMI ≥ 35 with at least one obesity-related comorbidity
• Surgery performed at a CMS-certified bariatric surgery center of excellence (COE)
• Beneficiary has received multidisciplinary team evaluation
• No prior bariatric procedure in the last 3 years

Approved procedures include Roux-en-Y gastric bypass, laparoscopic adjustable gastric banding, and sleeve gastrectomy. Part A covers inpatient stays; Part B covers outpatient or same-day surgical procedures.

GLP-1 Medications (Part D)

As of 2024, Medicare Part D covers semaglutide (Wegovy) specifically for cardiovascular risk reduction — not solely for obesity — in adults with BMI ≥ 27 and established cardiovascular disease (prior heart attack, stroke, or peripheral artery disease). This coverage followed the FDA's approval of this expanded indication based on the SELECT trial.

Full Medicare coverage of GLP-1 drugs for obesity treatment without CVD is expected through CMS regulatory action, with implementation targeted for 2026. When implemented, an estimated 3.6 million Medicare beneficiaries would become newly eligible.

Intensive Behavioral Therapy (IBT) — Part B

Medicare Part B covers intensive behavioral counseling for obesity at zero patient cost when provided by a primary care physician or qualified non-physician practitioner in a primary care setting. The benefit includes:

• 1 high-intensity session (15+ minutes) per week for the first month
• 1 session every 2 weeks for months 2–6
• 1 monthly session for months 7–12 (if patient achieved ≥ 3 kg weight loss by month 6)

Medicaid Coverage by State

Medicaid coverage for obesity treatment is highly variable and set by each state's Medicaid program within federal guidelines. As of 2024:

Private / Employer Insurance

Coverage through employer-sponsored plans and ACA marketplace plans varies enormously. Key trends as of 2024–2025:

Bariatric Surgery

Approximately 72% of large employer plans (500+ employees) cover bariatric surgery, according to the International Foundation of Employee Benefit Plans. Requirements typically include BMI documentation, 3–6 months of supervised diet and exercise with documented results, psychological evaluation, and surgeon and facility network restrictions.

GLP-1 Weight Loss Medications

Despite the effectiveness of Wegovy and Zepbound, only about 25–35% of commercial plans currently include weight loss medications on formulary. Many plans that cover Ozempic or Mounjaro for diabetes specifically exclude the obesity-indicated versions (Wegovy, Zepbound) to limit cost. Employers' adoption is accelerating: a 2024 KFF survey found that 43% of large employers plan to add weight loss drug coverage in the next 2 years.

How to Get Prior Authorization Approved

Prior authorization (PA) is required by nearly all plans for bariatric surgery and GLP-1 medications. Follow these steps to maximize approval chances:

1. Document your BMI precisely — Use measured height and weight from a clinical visit, not self-reported data.
2. Record failed interventions — Document participation in a supervised diet program, behavioral counseling, or previous medications with dates and outcomes.
3. List all comorbidities — Hypertension, T2D, sleep apnea, GERD, joint disease, and cardiovascular risk factors all strengthen medical necessity.
4. Get a detailed letter of medical necessity (LMN) — Your prescriber should cite relevant clinical guidelines (ASMBS, ACC/AHA, Obesity Medicine Association) and peer-reviewed evidence.
5. Ask about step therapy requirements — Some plans require failure of a lower-cost drug first. If so, request that medication and document the trial.
6. File the appeal immediately on denial — You typically have 30–180 days to file. Request peer-to-peer review between your doctor and the plan's medical director.

Manufacturer Patient Assistance Programs

Both Novo Nordisk and Eli Lilly offer savings programs to reduce out-of-pocket cost for commercially insured patients:

• Novo Nordisk Patient Assistance Program: Wegovy savings card can reduce monthly cost to as low as $25 for eligible commercially insured patients.
• Eli Lilly Savings Card (Zepbound): Can reduce cost to $25–$99/month for eligible patients.
• Uninsured patients below certain income thresholds may qualify for free medication through manufacturer patient assistance programs.

Frequently Asked Questions